Dyslipidemia | Unmet Need | US/EU | 2016
The most common problems associated with treating dyslipidemia are identifying patients who need to be treated, determining how aggressively they should be treated, and then encouraging them to comply with prescribed therapy. In addition, the degree of cardioprotection afforded by current agents is often suboptimal. Decision Resources Group’s Unmet Needs in Dyslipidemia analysis provides quantitative insight into U.S. and European physician perceptions of the unmet needs associated with dyslipidemia treatment, the goals of treatment, and the key drivers of therapy uptake. We discuss the commercial opportunities and how emerging therapies can capitalize on these opportunities.
Related Market Assessment Reports
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
